THE SUSTAINABILITY LEADERS
RECIPHARM: OVERCOMING CHALLENGES TO REDUCE CARBON EMISSIONS IN THE PHARMACEUTICAL INDUSTRY Driven by carbon and other greenhouse gas (GHG) emissions, global temperatures have already increased by 1.2°C compared with just over a century ago, causing climate change. With atmospheric CO2 levels continuing to rise, changes are required to prevent further warming [1]. To minimise the impact of climate change, 195 countries, including the European Union (EU), signed the 2015 Paris Agreement to keep global warming under 1.5°C. They committed their economies to a 45%
DRUG, CHEMICAL & ASSOCIATED TECHNOLOGIES ASSOCIATION (DCAT)
reduction of GHG emissions by 2030 and to reaching net zero by 2050 [2]. To help tackle climate change, the pharmaceutical industry must reduce its contribution to carbon emissions. This requires coordination with the wider industry to account for every aspect of company operations and supply chains, identifying how CO2 and other GHG emissions can be removed from key processes. In addition, any energy-saving opportunities identified should be integrated into current operations.
WWW.DCAT.ORG
31